ArticleBMC complementary medicine and therapies2026
The integration of network pharmacology and multiomics reveals the mechanism by which Malus hupehensis leaves inhibit acute liver injury.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThe leaves of Malus hupehensis (MH) are a medicinal and edible TCM with good liver protection, although its underlying mechanism remains unclear. In this study, a network pharmacology-integrated multiomics method was used to explore the hepatoprotective mechanism of MH.
methodsThe in vivo and in vitro components of MH were identified using ultra-performance liquid chromatography coupled with Q Exactive Orbitrap mass spectrometry (UPLC-Q Exactive Orbitrap-MS), and the targets and related pathways through which MH inhibits acute liver injury (ALI) were predicted by network pharmacology. The liver protective potential of MH was evaluated in a carbon tetrachloride-induced ALI model in C57BL/6J mice. The mechanism of MH was explored by integrating network pharmacology and multiomics and verified by immunohistochemistry, Western blot and RT‒qPCR analyses.
resultsOur analysis revealed 121 in vitro and 20 in vivo components of MH. The network pharmacology analysis showed that the prototype components of MH, phlorizin and phloretin, were involved in inflammation and metabolism-related pathways. In vivo experiments revealed that MH significantly inhibited carbon tetrachloride-induced ALI in mice through antioxidant and anti-inflammatory effects. Combined network pharmacology and multiomics analyses revealed that MH protected the liver by inhibiting the activation of the MAPK signaling pathway and regulating metabolic reprogramming, specifically with respect to lipid and amino acid metabolism.
conclusionsOur study suggests that MH exerts a protective effect on carbon tetrachloride-induced ALI in mice, potentially by inhibiting MAPK signaling and regulating lipid and amino acid metabolic reprogramming. These findings provide a preliminary basis for exploring MH as a potential candidate for the prevention and treatment of ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.